In the SPARC trial, what was the cumulative incidence of grade 2+ GU adverse events over 2 years following prostate SBRT with focal boost?
In a recent randomized trial, did low dose whole brain RT improve PFS in patients with primary CNS lymphoma?
Did concurrent and adjuvant atezolizumab improve OS in patients receiving chemoradiation for limited stage SCLC?
Answers
35% after 36.25 Gy in 5 fractions with a SIB of 47.5 Gy to the dominant nodule.
Yes, 79% v 54% at 2 years with 23.4 Gy in 13 fractions. Complete response rate was 92% v 76%.
No. In LU005, OS at 2 years was 59.2% with CRT + atezo and 63% with CRT. Median PFS was 12.1 v 11.4 months. | QuadShot News
In a recent randomized trial, did low dose whole brain RT improve PFS in patients with primary CNS lymphoma?
Did concurrent and adjuvant atezolizumab improve OS in patients receiving chemoradiation for limited stage SCLC?
Answers
35% after 36.25 Gy in 5 fractions with a SIB of 47.5 Gy to the dominant nodule.
Yes, 79% v 54% at 2 years with 23.4 Gy in 13 fractions. Complete response rate was 92% v 76%.
No. In LU005, OS at 2 years was 59.2% with CRT + atezo and 63% with CRT. Median PFS was 12.1 v 11.4 months. | QuadShot News